Limits...
Orthogonal polarisation spectral imaging as a new tool for the assessment of antivascular tumour treatment in vivo: a validation study.

Pahernik S, Harris AG, Schmitt-Sody M, Krasnici S, Goetz AE, Dellian M, Messmer K - Br. J. Cancer (2002)

Bottom Line: Correlation parameters for diameter of microvessels and red blood cell velocity were similar (r2=0.97, R(S)=0.99 and r2=0.93, R(S)=0.94 for diameter of microvessels and red blood cell velocity, respectively).Treatment with SU5416 reduced tumour angiogenesis.In addition to the inhibition of tumour angiogenesis, tumour growth and the development of metastasis was strongly reduced in SU5416 treated animals.

View Article: PubMed Central - PubMed

Affiliation: Institute for Surgical Research, Klinikum Grosshadern, University of Munich, Marchioninistrasse 15, 81377 Munich, Germany. Pahernik@Urologie.Klinik.Uni-Mainz.de

Show MeSH

Related in: MedlinePlus

(A) Functional microvessel density was assessed by OPS imaging for control and SU5416 treated animals, *P<0.05 SU5416 vs control, #P<0.05 day 3 vs day 6. (B) Tumour growth in control and SU5416 treated animals, *P<0.05 SU5416 vs control.
© Copyright Policy
Related In: Results  -  Collection


getmorefigures.php?uid=PMC2746600&req=5

fig5: (A) Functional microvessel density was assessed by OPS imaging for control and SU5416 treated animals, *P<0.05 SU5416 vs control, #P<0.05 day 3 vs day 6. (B) Tumour growth in control and SU5416 treated animals, *P<0.05 SU5416 vs control.

Mentions: Treatment of tumours with SU5416 reduced the formation of new vessels. The functional vessel density of tumours monitored by OPS for control and SU5416 treated animals, respectively, was 66.6±10.1 and 4.8±2.1 cm−1 at day 3 after tumour cell implantation (P<0.05), 147.4±13.2 and 87.2±10.2 cm−1 at day 6 (P<0.05), and 119.7±7.2 and 106.1±14.7 cm−1 at day 9 (Figure 5A). With respect to red blood cell velocity there were no significant differences between the groups: Red blood cell velocity was 0.09±0.03 and 0.03±0.01 mm s−1 at day 3, 0.08±0.02 and 0.11±0.04 mm s−1 at day 6, and 0.09±0.02 and 0.07±0.02 mm s−1 at day 9 after tumour cell implantation, for control and SU5416 treated animals, respectively. Similarly, no effect of SU5416 treatment on microvascular diameter could be noted. Microvessel diameter was 17.6±2.1 and 12.6±3.8 μm at day 3, 14.5±1.4 and 15.2±1.5 μm at day 6, and 16.6±0.4 and 15.3±2.5 μm at day 9 after tumour cell implantation, for control and SU5416 treated animals, respectively.


Orthogonal polarisation spectral imaging as a new tool for the assessment of antivascular tumour treatment in vivo: a validation study.

Pahernik S, Harris AG, Schmitt-Sody M, Krasnici S, Goetz AE, Dellian M, Messmer K - Br. J. Cancer (2002)

(A) Functional microvessel density was assessed by OPS imaging for control and SU5416 treated animals, *P<0.05 SU5416 vs control, #P<0.05 day 3 vs day 6. (B) Tumour growth in control and SU5416 treated animals, *P<0.05 SU5416 vs control.
© Copyright Policy
Related In: Results  -  Collection

Show All Figures
getmorefigures.php?uid=PMC2746600&req=5

fig5: (A) Functional microvessel density was assessed by OPS imaging for control and SU5416 treated animals, *P<0.05 SU5416 vs control, #P<0.05 day 3 vs day 6. (B) Tumour growth in control and SU5416 treated animals, *P<0.05 SU5416 vs control.
Mentions: Treatment of tumours with SU5416 reduced the formation of new vessels. The functional vessel density of tumours monitored by OPS for control and SU5416 treated animals, respectively, was 66.6±10.1 and 4.8±2.1 cm−1 at day 3 after tumour cell implantation (P<0.05), 147.4±13.2 and 87.2±10.2 cm−1 at day 6 (P<0.05), and 119.7±7.2 and 106.1±14.7 cm−1 at day 9 (Figure 5A). With respect to red blood cell velocity there were no significant differences between the groups: Red blood cell velocity was 0.09±0.03 and 0.03±0.01 mm s−1 at day 3, 0.08±0.02 and 0.11±0.04 mm s−1 at day 6, and 0.09±0.02 and 0.07±0.02 mm s−1 at day 9 after tumour cell implantation, for control and SU5416 treated animals, respectively. Similarly, no effect of SU5416 treatment on microvascular diameter could be noted. Microvessel diameter was 17.6±2.1 and 12.6±3.8 μm at day 3, 14.5±1.4 and 15.2±1.5 μm at day 6, and 16.6±0.4 and 15.3±2.5 μm at day 9 after tumour cell implantation, for control and SU5416 treated animals, respectively.

Bottom Line: Correlation parameters for diameter of microvessels and red blood cell velocity were similar (r2=0.97, R(S)=0.99 and r2=0.93, R(S)=0.94 for diameter of microvessels and red blood cell velocity, respectively).Treatment with SU5416 reduced tumour angiogenesis.In addition to the inhibition of tumour angiogenesis, tumour growth and the development of metastasis was strongly reduced in SU5416 treated animals.

View Article: PubMed Central - PubMed

Affiliation: Institute for Surgical Research, Klinikum Grosshadern, University of Munich, Marchioninistrasse 15, 81377 Munich, Germany. Pahernik@Urologie.Klinik.Uni-Mainz.de

Show MeSH
Related in: MedlinePlus